{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:38:37Z","timestamp":1793216317074,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.lungcan.2023.107321","type":"journal-article","created":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T08:03:10Z","timestamp":1691308990000},"page":"107321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Impact of first-line immunotherapy on survival and intracranial outcomes in a cohort of non-small cell lung cancer patients with brain metastases at diagnosis"],"prefix":"10.1016","volume":"184","author":[{"given":"Benoit","family":"Nigen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Goronflot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Herbreteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mathiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Sagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Raimbourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaafar","family":"Bennouna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Thillays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4478-0523","authenticated-orcid":false,"given":"Elvire","family":"Pons-Tostivint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2023.107321_b0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"11","key":"10.1016\/j.lungcan.2023.107321_b0010","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107321_b0015","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1016\/j.cllc.2018.01.007","article-title":"Non-small-cell Lung Cancer With Brain Metastasis at Presentation","volume":"19","author":"Waqar","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107321_b0020","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1200\/EDBK_100006","article-title":"Targeted Therapy in Brain Metastases: Ready for Primetime?","volume":"35","author":"Venur","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.lungcan.2023.107321_b0025","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"issue":"28","key":"10.1016\/j.lungcan.2023.107321_b0030","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.22.00825","article-title":"Therapy for Stage IV Non\u2013Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline","volume":"40","author":"Singh","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.lungcan.2023.107321_b0035","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10274","key":"10.1016\/j.lungcan.2023.107321_b0040","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.lungcan.2023.107321_b0045","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus Chemotherapy for Squamous Non\u2013Small-Cell Lung Cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2023.107321_b0050","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non\u2013Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"JCO"},{"issue":"14","key":"10.1016\/j.lungcan.2023.107321_b0055","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for First-Line Treatment of PD-L1\u2013Selected Patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10027","key":"10.1016\/j.lungcan.2023.107321_b0060","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"10066","key":"10.1016\/j.lungcan.2023.107321_b0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.lungcan.2023.107321_b0070","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10183","key":"10.1016\/j.lungcan.2023.107321_b0075","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet."},{"issue":"25","key":"10.1016\/j.lungcan.2023.107321_b0080","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line Nivolumab in Stage IV or Recurrent Non\u2013Small-Cell Lung Cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2023.107321_b0085","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non\u2013Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107321_b0090","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol. f\u00e9vr"},{"issue":"8","key":"10.1016\/j.lungcan.2023.107321_b0095","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jtho.2021.04.014","article-title":"Immunotherapy as Single Treatment for Patients With NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis\u2014the META-L-BRAIN Study","volume":"16","author":"Loiola","year":"2021","journal-title":"J. Thoracic Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107321_b0100","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1007\/s00262-022-03224-2","article-title":"Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis","volume":"71","author":"Chen","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"8","key":"10.1016\/j.lungcan.2023.107321_b0105","article-title":"Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042","volume":"2","author":"Mansfield","year":"2021","journal-title":"JTO Clin Res Rep. ao\u00fbt"},{"issue":"11","key":"10.1016\/j.lungcan.2023.107321_b0110","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","article-title":"Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407","volume":"16","author":"Powell","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107321_b0115","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol. mai"},{"issue":"10","key":"10.1016\/j.lungcan.2023.107321_b0120","doi-asserted-by":"crossref","first-page":"S863","DOI":"10.1016\/j.jtho.2021.08.062","article-title":"OA09.02 Atezo-Brain: Single Arm Phase II Study of Atezolizumab Plus Chemotherapy in Stage IV NSCLC With Untreated Brain Metastases","volume":"16","author":"Nadal","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107321_b0125","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jtho.2023.01.083","article-title":"Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study","volume":"18","author":"Hou","year":"2023","journal-title":"J Thorac Oncol. juin"},{"issue":"2","key":"10.1016\/j.lungcan.2023.107321_b0130","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2023.107321_b0135","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.lungcan.2023.107321_b0140","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","article-title":"Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)","volume":"3","author":"Sperduto","year":"2017","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107321_b0145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2022.03.020","volume":"114","author":"Sperduto","year":"2022","journal-title":"Int. J. Radiation Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107321_b0150","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.annonc.2022.02.008","article-title":"Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data","volume":"33","author":"P\u00e9rol","year":"2022","journal-title":"Ann Oncol. mai"},{"key":"10.1016\/j.lungcan.2023.107321_b0155","article-title":"Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 \u2265 50","author":"Pons-Tostivint","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lungcan.2023.107321_b0160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2021.04.007","article-title":"Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer","volume":"156","author":"Waterhouse","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107321_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103460","article-title":"Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review","volume":"166","author":"Schoenmaekers","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.lungcan.2023.107321_b0170","article-title":"Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.lungcan.2023.107321_b0175","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jtho.2021.04.014","article-title":"Immunotherapy as Single Treatment for Patients With NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis-the META-L-BRAIN Study","volume":"16","author":"Loiola","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107321_b0180","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"JCO"},{"issue":"11","key":"10.1016\/j.lungcan.2023.107321_b0185","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO\u2013ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann. Oncol."},{"issue":"10055","key":"10.1016\/j.lungcan.2023.107321_b0190","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","volume":"388","author":"Mulvenna","year":"2016","journal-title":"Lancet"},{"issue":"Supplement","key":"10.1016\/j.lungcan.2023.107321_b0195","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3171\/JNS\/2008\/109\/12\/S14","article-title":"A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment","volume":"109","author":"Sperduto","year":"2008","journal-title":"J Neurosurg. d\u00e9c"},{"issue":"3","key":"10.1016\/j.lungcan.2023.107321_b0200","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11060-017-2398-8","article-title":"Comparing available criteria for measuring brain metastasis response to immunotherapy","volume":"132","author":"Qian","year":"2017","journal-title":"J Neurooncol."},{"key":"10.1016\/j.lungcan.2023.107321_b0205","unstructured":"Commissioner O of the. U.S. Food and Drug Administration. FDA; 2021 [cit\u00e9 6 d\u00e9c 2022]. Evaluating Cancer Drugs in Patients with Central Nervous System Metastases. Disponible sur: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/evaluating-cancer-drugs-patients-central-nervous-system-metastases."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:05:45Z","timestamp":1759237545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223008590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":41,"alternative-id":["S0169500223008590"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107321","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of first-line immunotherapy on survival and intracranial outcomes in a cohort of non-small cell lung cancer patients with brain metastases at diagnosis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107321"}}